- Home
- OPHC vs MAIA Comparison
OPHC vs MAIA Comparison
Compare OPHC & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- MAIA
- Stock Information
- Founded
- OPHC 2000
- MAIA 2018
- Country
- OPHC United States
- MAIA United States
- Employees
- OPHC N/A
- MAIA N/A
- Industry
- OPHC Major Banks
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- OPHC Finance
- MAIA Health Care
- Exchange
- OPHC Nasdaq
- MAIA Nasdaq
- Market Cap
- OPHC 43.1M
- MAIA 44.8M
- IPO Year
- OPHC N/A
- MAIA 2022
- Fundamental
- Price
- OPHC $4.04
- MAIA $1.55
- Analyst Decision
- OPHC Hold
- MAIA
- Analyst Count
- OPHC 1
- MAIA 0
- Target Price
- OPHC $5.25
- MAIA N/A
- AVG Volume (30 Days)
- OPHC 29.1K
- MAIA 75.2K
- Earning Date
- OPHC 05-12-2025
- MAIA 05-13-2025
- Dividend Yield
- OPHC N/A
- MAIA N/A
- EPS Growth
- OPHC 53.23
- MAIA N/A
- EPS
- OPHC 1.33
- MAIA N/A
- Revenue
- OPHC $37,091,000.00
- MAIA N/A
- Revenue This Year
- OPHC N/A
- MAIA N/A
- Revenue Next Year
- OPHC N/A
- MAIA N/A
- P/E Ratio
- OPHC $3.04
- MAIA N/A
- Revenue Growth
- OPHC 60.44
- MAIA N/A
- 52 Week Low
- OPHC $3.53
- MAIA $1.40
- 52 Week High
- OPHC $5.90
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- OPHC 50.02
- MAIA 46.60
- Support Level
- OPHC $3.68
- MAIA $1.41
- Resistance Level
- OPHC $3.98
- MAIA $1.61
- Average True Range (ATR)
- OPHC 0.15
- MAIA 0.11
- MACD
- OPHC 0.03
- MAIA 0.01
- Stochastic Oscillator
- OPHC 80.95
- MAIA 62.50
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides a range of community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal account, money market deposit accounts, debit cards, and automated teller machines.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.